Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2a,Condition 2b,Condition 2c,Condition 3a,Condition 3b 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0000770,SHRSP/Izm,male,84 days to 70 days,8,,CMO:0000037,hematocrit,,,,42,%,0.7071,2.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65523,control condition,,,,, 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0000770,SHRSP/Izm,male,150 days,7,,CMO:0000037,hematocrit,,,,44,%,1.1339,3.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65524,control condition,,,,, 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0001433,SHRSP.WKY-(D1Wox29-D1Arb21)/Izm,male,150 days,9,,CMO:0000037,hematocrit,,,,45,%,0.6667,2.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65525,control condition,,,,, 567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0001433,SHRSP.WKY-(D1Wox29-D1Arb21)/Izm,male,84 days to 70 days,7,,CMO:0000037,hematocrit,,,,43,%,0.378,1.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65526,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000037,hematocrit,,,median,46,%,,,MMO:0000214,hematocrit analysis,,0,,,,,control condition,66131,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000037,hematocrit,,,median,70,%,,,MMO:0000214,hematocrit analysis,,0,,,,,air oxygen content (10 %) (for 21 days),66132,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0001072,WKY/NCruk,male,105 days,12,,CMO:0000037,hematocrit,,,median,45,%,,,MMO:0000214,hematocrit analysis,,0,,,,,control condition,66133,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0001072,WKY/NCruk,male,105 days,28,,CMO:0000037,hematocrit,,,median,71,%,,,MMO:0000214,hematocrit analysis,,0,,,,,air oxygen content (10 %) (for 21 days),66134,air oxygen content (10 %) (for 21 days),,,,, 151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",erythrocyte quantity,,RS:0000145,BN/NHsdMcwi,female,92 days to 89 days,15,,CMO:0000037,hematocrit,,,,41.6,%,0.4,1.5492,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days),69481,controlled sodium content diet (0.4 %) (for 35 days),controlled sodium content diet (0.1 %) (for 35 days),,,controlled sodium content diet (8 %) (between 22 and 24 days), 151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",erythrocyte quantity,,RS:0000811,SS/JrHsdMcwi,female,92 days to 89 days,15,,CMO:0000037,hematocrit,,,,38.8,%,1.4,5.4222,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days),69482,controlled sodium content diet (0.4 %) (for 35 days),controlled sodium content diet (0.1 %) (for 35 days),,,controlled sodium content diet (8 %) (between 22 and 24 days), 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,9,,CMO:0000037,hematocrit,,,,47.3,%,0.9,2.7,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then enalapril (20 mg/kg/d) ,100851,right nephrectomy (for 56 days),enalapril (20 mg/kg/d) ,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,44,%,1.0,3.1623,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then lisinopril (10 mg/kg/d) ,100852,right nephrectomy (for 56 days),lisinopril (10 mg/kg/d) ,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,7,,CMO:0000037,hematocrit,,,,44.5,%,2.4,6.3498,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then angiotensin II receptor antagonist (20 mg/l) ,100853,right nephrectomy (for 56 days),angiotensin II receptor antagonist (20 mg/l) ,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,5,,CMO:0000037,hematocrit,,,,45,%,1.1,2.4597,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then angiotensin II receptor antagonist (80 mg/l) ,100854,right nephrectomy (for 56 days),angiotensin II receptor antagonist (80 mg/l) ,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,6,,CMO:0000037,hematocrit,,,,41.2,%,1.7,4.1641,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days),100855,right nephrectomy (for 112 days),,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,45.8,%,0.7,2.2136,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then reserpine (5 mg/l) (for 56 days) and hydralazine (80 mg/l) (for 56 days) and hydrochlorothiazide (25 mg/l) (for 56 days),100856,right nephrectomy (for 112 days),reserpine (5 mg/l) (for 56 days),hydralazine (80 mg/l) (for 56 days),hydrochlorothiazide (25 mg/l) (for 56 days),, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,45.3,%,1.1,3.4785,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then captopril (30 mg/kg/d) (for 56 days),100857,right nephrectomy (for 112 days),captopril (30 mg/kg/d) (for 56 days),,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,9,,CMO:0000037,hematocrit,,,,44.6,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then enalapril (20 mg/kg/d) (for 56 days),100858,right nephrectomy (for 112 days),enalapril (20 mg/kg/d) (for 56 days),,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,44,%,1.0,3.1623,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then lisinopril (10 mg/kg/d) (for 56 days),100859,right nephrectomy (for 112 days),lisinopril (10 mg/kg/d) (for 56 days),,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,7,,CMO:0000037,hematocrit,,,,40.5,%,2.1,5.5561,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then angiotensin II receptor antagonist (20 mg/l) (for 56 days),100860,right nephrectomy (for 112 days),angiotensin II receptor antagonist (20 mg/l) (for 56 days),,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,5,,CMO:0000037,hematocrit,,,,41,%,1.9,4.2485,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then angiotensin II receptor antagonist (80 mg/l) (for 56 days),100861,right nephrectomy (for 112 days),angiotensin II receptor antagonist (80 mg/l) (for 56 days),,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,6,,CMO:0000037,hematocrit,,,,44.8,%,0.6,1.4697,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days),100848,right nephrectomy (for 56 days),,,,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,48.4,%,1.4,4.4272,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then reserpine (5 mg/l) and hydralazine (80 mg/l) and hydrochlorothiazide (25 mg/l) ,100849,right nephrectomy (for 56 days),reserpine (5 mg/l) ,hydralazine (80 mg/l) ,hydrochlorothiazide (25 mg/l) ,, 2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,46.7,%,0.8,2.5298,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then captopril (30 mg/kg/d) ,100850,right nephrectomy (for 56 days),captopril (30 mg/kg/d) ,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,11,,CMO:0000037,hematocrit,,,,45.2,%,1.4,4.6433,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99975,unilateral nephrectomy (for 28 days),vehicle control condition,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,44.8,%,0.6,2.4739,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99976,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,,vehicle control condition, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,45.6,%,0.3,1.2369,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99977,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,,bosentan (100 mg/kg/d) (for 154 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.5,2.0,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99978,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 154 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,44.5,%,0.6,2.4,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99979,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days) 2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000786,SR/Jr,male,63 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.4,1.6,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 35 days) then anesthetic/analgesic,103266,controlled sodium content diet (0.3 %) (for 35 days),anesthetic/analgesic,,,, 2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000786,SR/Jr,male,63 days,13,,CMO:0000037,hematocrit,,,,43.5,%,0.5,1.8028,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 35 days) then anesthetic/analgesic,103267,controlled sodium content diet (8 %) (for 35 days),anesthetic/analgesic,,,, 2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000817,SS/Jr,male,63 days,15,,CMO:0000037,hematocrit,,,,48.8,%,0.5,1.9365,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 35 days) then anesthetic/analgesic,103268,controlled sodium content diet (0.3 %) (for 35 days),anesthetic/analgesic,,,, 2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000817,SS/Jr,male,63 days,10,,CMO:0000037,hematocrit,,,,47,%,2.2,6.957,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 35 days) then anesthetic/analgesic,103269,controlled sodium content diet (8 %) (for 35 days),anesthetic/analgesic,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",erythrocyte quantity,,RS:0003076,SS-Nppbem2Mcwi+/+,male,252 days,6,,CMO:0000037,hematocrit,,,,52.3,%,1.8,4.4091,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition (for 252 days),99736,control condition (for 252 days),,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",erythrocyte quantity,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,6,,CMO:0000037,hematocrit,,,,50.6,%,1.3,3.1843,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition (for 252 days),99737,control condition (for 252 days),,,,, 2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,40,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then control condition,100986,nephrectomy (for 28 days),control condition,,,, 2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,38,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then enalapril (50 mg/l) (for 21 days),100987,nephrectomy (for 28 days),enalapril (50 mg/l) (for 21 days),,,, 2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,36,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then reserpine (5 mg/l) (for 21 days) and hydralazine (80 mg/l) (for 21 days) and hydrochlorothiazide (25 mg/l) (for 21 days),100988,nephrectomy (for 28 days),reserpine (5 mg/l) (for 21 days),hydralazine (80 mg/l) (for 21 days),hydrochlorothiazide (25 mg/l) (for 21 days),, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,41,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100436,0.9% sodium chloride solution (3 ml) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,7,,CMO:0000037,hematocrit,,,,39,%,1.0,2.6458,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100437,puromycin aminonucleoside (50 mg/kg) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,5,,CMO:0000037,hematocrit,,,,35,%,1.0,2.2361,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100438,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,45,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100439,0.9% sodium chloride solution (3 ml) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,43,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100440,puromycin aminonucleoside (50 mg/kg) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,43,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100441,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,44,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100442,0.9% sodium chloride solution (3 ml) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,44,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100443,puromycin aminonucleoside (50 mg/kg) ,,,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,42,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100444,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,, 2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",erythrocyte quantity,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0000037,hematocrit,,,,50,%,0.3536,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,100913,control condition,,,,, 2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",erythrocyte quantity,,RS:0003240,MWF/ZtmRrrc,male,126 days,10,,CMO:0000037,hematocrit,,,,51,%,0.3162,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100914,enalapril (50 mg/l) (for 60 days),,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,56 days,20,,CMO:0000037,hematocrit,,,,47.6,%,0.0224,0.1,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) ,107810,DHD/K12/TRb cells (1.5 X 10E6) ,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000037,hematocrit,,,,52.3,%,0.9487,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107811,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml) ,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000037,hematocrit,,,,52.7,%,0.6957,2.2,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107812,DHD/K12/TRb cells (1.5 X 10E6) ,sanguinarine (5 mg/kg/d) ,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000037,hematocrit,,,,51,%,1.0436,3.3,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107813,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml) ,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000037,hematocrit,,,,44,%,0.9803,3.1,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107814,DHD/K12/TRb cells (1.5 X 10E6) ,sanguinarine (5 mg/kg/d) ,,,,